News

C3i is pleased to partner with Octane Orthobiologics Inc and Orthopaedic Innovation Center Inc with the support of NGen for automation and scale up the biomanufacturing of cartilage implants for commercial-level production. NGen has announced over $32.3 million in Global Innovation Cluster funding for 15 new advanced manufacturing projects. With industry contributions of $54.4 million, […]

The Montreal-based CDMO C3i Center Inc is paving the way in the cell and gene therapy industry in North American and Canada as one of a few contract development and manufacturing organizations (CDMOs) to be producing in North America and for Europe. “We are proud of our team has worked very hard to be able […]

C3i is a platinum sponsor for the Alliance for Regenerative Medicine’s 2023 Cell and Gene Meeting on the Mesa from October 10 – 12, 2023. We look forward to connecting with senior executives and top stakeholders to tackle the most pressing issues in cell and gene therapies. To learn more about this event: https://meetingonthemesa.com/ See […]

C3i CEO Louisa Petropoulos was recently featured in Outsourced Pharma online, discussing the present and future prospects of contract research organizations and Canadian innovation, as well as C3i’s accomplishments upon its 5th anniversary. Click here to read the story.

The C3i Center (C3i) is proud to announce the participation of AstraZeneca Canada (AstraZeneca) in supporting the development of the Lymphoma Registry. This state of the art registry, launched in September 2017 under the leadership of Dr. Isabelle Fleury, hematologist and medical oncologist at Institut universitaire d’hématologie-oncologie-thérapie cellulaire (IUHOTC) at Centre intégré universitaire de santé […]

C3i Center Inc. has strengthened our position as Canada’s leading one-stop contract development and manufacturing organization operating in the cell therapy space with two important developments.

An innovative treatment for advanced metastatic HER2-positive tumours has been administered to the first patient in a phase I/II clinical trial. The investigational T-cell antigen coupler adoptive immunotherapy, TAC01-HER2 will be given to as many as 70 patients in the TACTIC-2 trial, which is enrolling patients initially at three locations in the U.S. Developed by […]

C3i Center Inc (Formerly known Centre for Commercialisation of Cancer Immunotherapy) is proud to announce three new additions to its executive team. Louisa Petropoulos has been appointed new Chief Executive Officer, Eleonora Forero has been appointed Vice President of Operations, and Olivier Mailloux has been appointed Vice President of Finance and Chief Financial Officer. This […]

Behind every triumphant headline announcing a new breakthrough medicine, there’s an often untold story of years or even decades of basic research in the lab, and mad scrambles for funding to perform animal model studies and early stage human clinical trials that attract industry investment to move into larger trials. Layer onto that burden the […]